# EDGAR Filing Document

**Accession Number:** 0001460329
**File Stem:** 0001104659-25-083088
**Filing Date:** 2025-8
**Character Count:** 16595
**Document Hash:** 12f94d974e508f1bc8cdb21c66845612
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-083088.hdr.sgml**: 20250826

**ACCESSION NUMBER**: 0001104659-25-083088

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250826

**DATE AS OF CHANGE**: 20250826

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fluent, Inc.
- **CENTRAL INDEX KEY:** 0001460329
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-ADVERTISING [7310]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 770688094
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-85074
- **FILM NUMBER:** 251257789

**BUSINESS ADDRESS:**
- **STREET 1:** 300 VESEY STREET
- **STREET 2:** 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10282
- **BUSINESS PHONE:** 6466697272

**MAIL ADDRESS:**
- **STREET 1:** 300 VESEY STREET
- **STREET 2:** 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10282

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cogint, Inc.
- **DATE OF NAME CHANGE:** 20160923

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IDI, Inc.
- **DATE OF NAME CHANGE:** 20150520

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tiger Media, Inc.
- **DATE OF NAME CHANGE:** 20121231
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FROST PHILLIP MD ET AL
- **CENTRAL INDEX KEY:** 0000898860

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 4400 BISCAYNE BLVD
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33137-3227

## Exhibit 99.6

**Exhibit 99.6**

JOINT FILING AGREEMENT

The undersigned hereby agree that this Statement on Schedule 13D, and any amendments thereto filed by any of us, with respect to the securities of Fluent, Inc. described in this document, signed by each of the undersigned, shall be filed on behalf of each the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

---

| | | |
|:---|:---|:---|
| Dated: August 26, 2025 | /s/ Phillip Frost, M.D. | /s/ Phillip Frost, M.D. |
|  | Phillip Frost, M.D., individually | Phillip Frost, M.D., individually |
|  | FROST GAMMA INVESTMENTS TRUST | FROST GAMMA INVESTMENTS TRUST |
| Dated: August 26, 2025 | By: | /s/ Phillip Frost, M.D. |
|  | Phillip Frost, M.D., Trustee | Phillip Frost, M.D., Trustee |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 26)**

**Fluent, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0005 per share**

*(Title of Class of Securities)*

**34380C201**

*(CUSIP Number)*

**Daniel Barsky, Esq.**<br>300 Vesey Street, 9th Floor<br>New York NY 10282<br>(646) 669-7272

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/19/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **34380C201** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Phillip Frost, M.D.** | Name of reporting person<br>**Phillip Frost, M.D.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**8334.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7294403.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**8334.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7294403.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7302737.00** | Aggregate amount beneficially owned by each reporting person<br>**7302737.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**28.3%** | Percent of class represented by amount in Row (11)<br>**28.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) Frost Gamma Investments Trust ("Gamma Trust") beneficially owns 7,294,403 shares of common stock, which includes 66,667 shares of the Issuer's common stock underlying the convertible subordinated promissory note entered into pursuant to that certain securities purchase agreement, dated August 19, 2024 (the "Convertible Note"), 909,297 shares of common stock underlying warrants issued on May 19, 2025, and 571,429 shares of common stock underlying the Unregistered Pre-Funded Warrants (as defined below) on August 19, 2025. Dr. Phillip Frost is the trustee of Gamma Trust. Frost Gamma L.P. is the sole and exclusive beneficiary of Gamma Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation.

(2) Based on 24,268,299 shares of the Issuer's common stock outstanding as of August 18, 2025 (as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 19, 2025).

| **CUSIP No.** | **34380C201** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Frost Gamma Investments Trust** | Name of reporting person<br>**Frost Gamma Investments Trust** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**FLORIDA** | Citizenship or place of organization<br>**FLORIDA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7294403.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7294403.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7294403.00** | Aggregate amount beneficially owned by each reporting person<br>**7294403.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**28.3%** | Percent of class represented by amount in Row (11)<br>**28.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1) Gamma Trust beneficially owns 7,294,403 shares of common stock, which includes 66,667 shares of the Issuer's common stock underlying the Convertible Note and 909,297 shares of common stock underlying warrants issued on May 19, 2025, and 571,429 shares of common stock underlying the Unregistered Pre-Funded Warrants on August 19, 2025. Dr. Phillip Frost is the trustee of Gamma Trust. Frost Gamma L.P. is the sole and exclusive beneficiary of Gamma Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation.

(2) Based on 24,268,299 shares of the Company's common stock outstanding as of August 18, 2025 (as reported in the Company's Form 10-Q filed with the Securities and Exchange Commission on August 19, 2025).

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0005 per share

**(b) Name of Issuer:**
Fluent, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
300 Vesey Street, 9th Floor, New York, NY, 10282

This Schedule 13D is filed by the Reporting Person with respect to shares of common stock, par value $0.0005 per share, of Fluent, Inc., a Delaware corporation (the "Issuer" or the "Company"), formerly known as Cogint, Inc., formerly known as IDI, Inc., the successor to Tiger Media, Inc., SearchMedia Holdings Limited, Ideation Acquisition Corp. and ID Arizona Corp. The principal executive offices of the Issuer are located at 300 Vesey Street, 9th Floor, New York, New York 10282.

EXPLANATORY NOTE

This Amendment No. 26 (the "Amendment") amends and supplements the statement on Schedule 13D filed on December 6, 2007, as amended by Amendment No. 1 to the Schedule 13D filed on October 15, 2008, Amendment No. 2 to the Schedule 13D filed on April 13, 2009, Amendment No. 3 to the Schedule 13D filed on May 1, 2009, Amendment No. 4 to the Schedule 13D filed on July 14, 2009, Amendment No. 5 to the Schedule 13D filed on December 24, 2009, Amendment No. 6 to the Schedule 13D filed on November 22, 2011, Amendment No. 7 to the Schedule 13D filed on July 20, 2012, Amendment No. 8 to the Schedule 13D filed on August 23, 2012, Amendment No. 9 to the Schedule 13D filed on January 17, 2013, Amendment No. 10 to the Schedule 13D filed on July 12, 2013, Amendment No. 11 to the Schedule 13D filed on February 14, 2014, Amendment No. 12 to the Schedule 13D filed on April 6, 2015, Amendment No. 13 to the Schedule 13D filed on January 20, 2016, Amendment No. 14 to the Schedule 13D filed on March 29, 2016, Amendment No. 15 to the Schedule 13D filed on May 18, 2016, Amendment No. 16 to the Schedule 13D filed on July 21, 2016, Amendment No. 17 to the Schedule 13D filed on December 28, 2016, Amendment No. 18 to the Schedule 13D filed on December 22, 2017, Amendment No. 19 to the Schedule 13D filed on April 6, 2018, Amendment No. 20 to the Schedule 13D filed on February 14, 2019, Amendment No. 21 to the Schedule 13D filed on September 25, 2023, Amendment No. 22 filed on May 20, 2024, Amendment No. 23 filed on August 26, 2024, Amendment No. 24 filed on April 2, 2025 and Amendment No. 25 filed on May 23, 2025 (together the "Original Schedule 13D"), by Phillip Frost, M.D. ("Frost") and Frost Gamma Investments Trust ("Gamma Trust") (collectively, the "Reporting Person").

**Item 4. Purpose of Transaction**

Item 4 is hereby amended and restated to read as follows.

On August 19, 2025, Gamma Trust entered into a securities purchase agreement (the "Purchase Agreement") with the Company, pursuant to which Gamma Trust subscribed for $1,000,000 aggregate amount of (i) pre-funded warrants (the "Unregistered Pre-Funded Warrants") to purchase shares of common stock of the Company at a purchase price of $1.75 per Unregistered Pre-Funded Warrant and (ii) warrants (the "Warrants") to purchase shares of common stock of the Company with an exercise price of $2.21 per share of common stock. The aggregate exercise price of the Unregistered Pre-Funded Warrants (other than the nominal exercise price of $0.0005 per Unregistered Pre-Funded Warrant) was pre-funded. The Warrants are exercisable at any time on or after the date that is six months and one day following the date of issuance for a period of five years from the date of initial exercisability.

In connection with the Purchase Agreement, the Reporting Person and the Company entered into a Support Agreement with the Issuer pursuant to which the Reporting Person agreed to vote shares of the Issuer's common stock beneficially owned by him in favor of certain actions subject to Stockholder Approval (as defined in the Support Agreement) at any meeting of stockholders of the Issuer and to vote against or decline to consent to any proposal or any other corporate action or agreement that would result in a breach by the Issuer of the Purchase Agreement or impede, delay or otherwise adversely affect the consummation of the transactions contemplated by the Purchase Agreement or any similar agreements entered into by the Issuer and the stockholders a party thereto in connection with the consummation of the transactions contemplated by the Purchase Agreement.

Furthermore, in connection with the transactions described above, on August 19, 2025, Gamma Trust entered into a registration rights agreement (the "Registration Rights Agreement") with the Company, which provides that the Company is required to file a registration statement covering the resale of certain Registrable Securities (as defined in the Registration Rights Agreement).

The closing of the sales of the Unregistered Pre-funded Warrants and Warrants under the Purchase Agreement occurred on August 19, 2025.

The foregoing descriptions of the Unregistered Pre-Funded Warrant, Warrant, Purchase Agreement, Support Agreement and Registration Rights Agreement are not complete but are qualified in their entirety by reference to the full text of the form of  the Unregistered Pre-Funded Warrant, Warrant, Purchase Agreement, Support Agreement and Registration Rights Agreement, copies of which are attached hereto as Exhibits 99.1, 99.2, 99.3, 99.4 and 99.5, respectively, and are incorporated by reference herein.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person is the beneficial owner of 7,302,737 shares of common stock of the Issuer, which includes 66,667 shares of the Issuer's common stock underlying the Convertible Note and 909,297 shares of common stock underlying warrants issued on May 19, 2025, and 571,429 shares of common stock underlying of the Unregistered Pre-Funded Warrants on August 19, 2025, representing 28.3% of the Issuer's common stock. The percentage of beneficial ownership is based upon 24,268,299 shares of the Company's common stock outstanding as of August 18, 2025 (as reported in the Company's Form 10-Q filed with the Securities and Exchange Commission on August 19, 2025).

**(b)**
The information contained on the cover page to this Amendment is incorporated herein by reference.

**(c)**
Transactions in the Issuer's securities effected by the Reporting Person during the past sixty days:

The information set forth or incorporated under Item 4 is incorporated by reference in its entirety into this Item 5.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Schedule 13D is amended by adding the following paragraph:

The description in Item 4 and the agreements incorporated therein by reference and set forth as an exhibit hereto is incorporated herein by reference in answer to this Item 6.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Phillip Frost, M.D.

**Signature:** /s/ Phillip Frost, M.D.

**Name/Title:** Phillip Frost, M.D., individually

**Date:** 08/26/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Frost Gamma Investments Trust

**Signature:** /s/ Phillip Frost, M.D.

**Name/Title:** Phillip Frost, M.D., Trustee

**Date:** 08/26/2025